NASDAQ:ABOS Acumen Pharmaceuticals (ABOS) Stock Price, News & Analysis $2.35 +0.18 (+8.29%) Closing price 04:00 PM EasternExtended Trading$2.35 0.00 (-0.21%) As of 05:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Acumen Pharmaceuticals Stock (NASDAQ:ABOS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Acumen Pharmaceuticals alerts:Sign Up Key Stats Today's Range$2.18▼$2.3850-Day Range$2.17▼$3.3752-Week Range$0.99▼$3.60Volume342,549 shsAverage Volume673,960 shsMarket Capitalization$169.74 millionP/E RatioN/ADividend YieldN/APrice Target$6.67Consensus RatingModerate Buy Company Overview Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies for neurodegenerative diseases. Leveraging a proprietary drug discovery platform that integrates chemoproteomics, high-throughput screening and computational chemistry, the company seeks to identify and optimize compounds that selectively modulate pathological protein aggregation. Its approach is designed to address the underlying biology of conditions such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and related proteinopathies. The company’s pipeline comprises multiple lead candidates at various stages of preclinical and early clinical development. Its most advanced program targets abnormal tau aggregation in Alzheimer’s disease and has entered Phase 1 clinical testing. Additional preclinical candidates are designed to inhibit the misfolding or aggregation of proteins including TDP-43, alpha-synuclein, mutant huntingtin and transthyretin, with the goal of expanding its portfolio across a spectrum of neurodegenerative indications. Founded in 2019 and headquartered in San Diego, California, Acumen Pharmaceuticals has assembled a management team with extensive experience in small molecule drug discovery and neuroscience R&D. The company completed its initial public offering in mid-2023, raising capital to advance its lead program through clinical proof-of-concept and to prepare select preclinical candidates for first-in-human studies. Acumen’s research and development efforts are complemented by collaborations with academic laboratories and contract research organizations across North America. With a strategic focus on oral therapies that can be broadly administered in outpatient settings, Acumen aims to address significant unmet medical needs in the rapidly growing field of neurodegenerative disease treatment. The company’s leadership emphasizes rigorous translational science and biomarker-driven clinical development to accelerate the pathway from discovery to potential regulatory approval, ultimately seeking to improve quality of life for patients worldwide.AI Generated. May Contain Errors. Read More Acumen Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreABOS MarketRank™: Acumen Pharmaceuticals scored higher than 43% of companies evaluated by MarketBeat, and ranked 560th out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingAcumen Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialAcumen Pharmaceuticals has a consensus price target of $6.67, representing about 184.9% upside from its current price of $2.34.Amount of Analyst CoverageAcumen Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Acumen Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Acumen Pharmaceuticals are expected to decrease in the coming year, from ($1.43) to ($2.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Acumen Pharmaceuticals is -1.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acumen Pharmaceuticals is -1.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAcumen Pharmaceuticals has a P/B Ratio of 1.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.50% of the float of Acumen Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAcumen Pharmaceuticals has a short interest ratio ("days to cover") of 5.17.Change versus previous monthShort interest in Acumen Pharmaceuticals has recently increased by 8.47%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAcumen Pharmaceuticals does not currently pay a dividend.Dividend GrowthAcumen Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.5 / 5News Sentiment-0.05 News SentimentAcumen Pharmaceuticals has a news sentiment score of -0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Acumen Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest9 people have searched for ABOS on MarketBeat in the last 30 days. This is an increase of 350% compared to the previous 30 days.MarketBeat Follows8 people have added Acumen Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Acumen Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders7.10% of the stock of Acumen Pharmaceuticals is held by insiders.Percentage Held by Institutions71.01% of the stock of Acumen Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Acumen Pharmaceuticals' insider trading history. Receive ABOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acumen Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ABOS Stock News HeadlinesAcumen's Late-2026 Sabirnetug Readout Is A Viable BetMay 20 at 8:03 AM | seekingalpha.comAcumen Pharma president Doherty sells $15k in ABOS stockMay 19 at 7:40 AM | investing.comI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, Amazon, Snap, and Block have done the same. Most assume this is about AI - but investor Porter Stansberry says the real driver runs far deeper. Goldman Sachs estimates 12,400 Americans are being financially harmed every day by this shift, while others grow wealthier. Stansberry - who predicted the internet economy's rise and recommended Amazon, Qualcomm, and Texas Instruments before they were household names - is now releasing a new investigation he calls The Final Displacement.May 20 at 1:00 AM | Porter & Company (Ad)Acumen Pharmaceuticals Sets Sights on Key Alzheimer's Drug Readout This YearMay 16, 2026 | americanbankingnews.comAcumen Pharmaceuticals, Inc. (ABOS) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 14, 2026 | seekingalpha.comAcumen Pharmaceuticals Warns Investors: Unchanged 10-K Risk Factors Still Weigh on Valuation and Share PriceMay 14, 2026 | tipranks.comAcumen Pharmaceuticals Bets Big on Alzheimer’s TrialsMay 12, 2026 | tipranks.comAcumen Pharmaceuticals Inc (ABOS) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...May 12, 2026 | finance.yahoo.comSee More Headlines ABOS Stock Analysis - Frequently Asked Questions How have ABOS shares performed this year? Acumen Pharmaceuticals' stock was trading at $2.11 at the beginning of the year. Since then, ABOS stock has increased by 10.9% and is now trading at $2.34. How were Acumen Pharmaceuticals' earnings last quarter? Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) posted its quarterly earnings results on Tuesday, May, 12th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.40) by $0.07. Read the conference call transcript. When did Acumen Pharmaceuticals IPO? Acumen Pharmaceuticals (ABOS) raised $150 million in an IPO on Tuesday, June 29th 2021. The company issued 9,999,999 shares at $14.00-$16.00 per share. Who are Acumen Pharmaceuticals' major shareholders? Acumen Pharmaceuticals' top institutional investors include ADAR1 Capital Management LLC (2.99%), SG Americas Securities LLC (1.00%), Renaissance Technologies LLC (0.66%) and Bank of America Corp DE (0.44%). Insiders that own company stock include Ra Capital Management, LP, Daniel Joseph Oconnell, Matt Zuga, Eric Siemers, Russell Barton, Derek M Meisner, James J Doherty and Jeffrey L Ives. View institutional ownership trends. How do I buy shares of Acumen Pharmaceuticals? Shares of ABOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Acumen Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Acumen Pharmaceuticals investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA) and Netflix (NFLX). Company Calendar Last Earnings5/12/2026Today5/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (10m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 ABOS's financial health is in the Green zone, according to TradeSmith. ABOS has been in this zone for over 10 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ABOS CIK1576885 Webwww.acumenpharm.com Phone434-297-1000FaxN/AEmployees20Year Founded1996Price Target and Rating Average Price Target for Acumen Pharmaceuticals$6.67 High Price Target$8.00 Low Price Target$4.00 Potential Upside/Downside+183.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$121.33 million Net MarginsN/A Pretax MarginN/A Return on Equity-123.07% Return on Assets-79.41% Debt Debt-to-Equity Ratio0.19 Current Ratio4.55 Quick Ratio4.55 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.21 per share Price / Book1.94Miscellaneous Outstanding Shares72,230,000Free Float67,100,000Market Cap$169.74 million OptionableOptionable Beta0.32 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:ABOS) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredAre we ignoring the same signal Wall Street ignored in 1929?In 1929, Irving Weiss spotted a systemic crisis hiding beneath record highs and shorted the market - turning $...Weiss Ratings | SponsoredIran War Update: Trump’s Hand-Written Letter Reveals What Comes NextJim Rickards has uncovered what he believes is Trump's economic plan, with a key trigger date of May 15. The F...Paradigm Press | SponsoredThis stock has 30 days of quiet leftA small power equipment company with $1.5 billion in orders is flying under the radar - but not for long. When...Behind the Markets | SponsoredThe Death of the Nasdaq?The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acumen Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acumen Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
